Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone versus placebo plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
MOH_2023-04-23_012560Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Janssen Pharmaceutical. Started Feb 2019; status: completed.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2023-04-23_012560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-23_012560.